Retron gene editing is one of the more counterintuitive ideas in modern molecular biology. Instead of synthesizing repair templates outside the cell and shipping them in, retrons let cells make single-stranded DNA templates inside themselves, on demand, in many copies, from a small genetic cassette. This solves one of the most stubborn problems in CRISPR: how to deliver enough template DNA to the right place at the right time. After two decades as an obscure curiosity of bacterial biology, retrons are now emerging as a serious platform for precision editing, directed evolution, and continuous in vivo mutagenesis — and they may be the missing piece that finally lets prime editing scale.
What Is a Retron?
A retron is a bacterial genetic element discovered in the 1980s in Myxococcus xanthus. It encodes three things on a single transcript: a non-coding RNA (msr-msd), a reverse transcriptase (RT), and — in many cases — an effector protein. The reverse transcriptase uses part of its own non-coding RNA as a template to synthesize a hybrid RNA-DNA molecule called multi-copy single-stranded DNA, or msDNA. Each retron-bearing bacterial cell can contain hundreds to thousands of msDNA copies.
For decades, no one knew what retrons were for. The 2020 Sorek and Kranzusch lab work and follow-up studies established that retrons are part of bacterial anti-phage immune systems — tripwires that detect phage infection and trigger abortive infection. The msDNA is the sentinel molecule.
The breakthrough for biotechnology was the realization that the msDNA-generating machinery could be hijacked: by replacing the natural msd template with a custom sequence, researchers could program bacteria — and later mammalian cells — to generate hundreds of copies of a chosen single-stranded DNA in situ. That ssDNA can then serve as a homology-directed repair template, a recombineering substrate, or a base for continuous mutagenesis.
How Retron Editing Works
The classical workflow has three steps:
1. Cassette delivery. A retron cassette is delivered into the cell, encoding (a) the reverse transcriptase, (b) the msr-msd RNA scaffold with a custom payload, and (c) optionally a CRISPR nuclease.
2. msDNA production. The RT transcribes the RNA scaffold and uses it as a template to synthesize ssDNA, leaving a chimeric RNA-DNA molecule. The DNA portion contains the user's payload — for instance, a 100 nt edit template.
3. Site-specific edit. A CRISPR nuclease (Cas9, Cas12, or a prime editor) makes a nick or cut, and the freshly produced ssDNA donor templates the repair via homology-directed repair or microhomology-mediated end joining.
The advantage over delivering exogenous ssDNA is enormous: every cell receives template, every cell generates many copies internally, and the template is regenerated continuously as long as the cassette is present. This is especially useful for continuous in vivo mutagenesis — running directed-evolution experiments inside living organisms.
Key Papers and Milestones
- Inouye et al., 1989. Original discovery of msDNA in Myxococcus xanthus.
- Farzadfard & Lu, 2014 (Science). First demonstration of retron-based DNA writing in bacteria as a "molecular recorder."
- Simon, Ellington et al., 2018. Engineering retrons for production of custom ssDNA in bacteria.
- Sharon, Chen, Khosla, Smith, Church et al., 2018 (Cell). CRISPEY — Cas9 plus retrons for high-throughput functional genomics in yeast.
- Lopez et al., 2022 (Nature Chemical Biology). Retron Library Recombineering (RLR) — massively parallel genome editing in bacteria.
- Schubert, Bondy-Denomy, Marraffini lab work, 2021–2022. Mechanistic studies showing retrons function as anti-phage defense.
- Millman, Bernheim, Stokar-Avihail, Sorek et al., 2020 (Cell). Retrons as part of bacterial immunity.
- Kong et al., 2024 (Nature Methods). Retron-based prime editing combinations in mammalian cells (Prime-Retron-Editor concepts).
- Crook & Voigt, 2023. Engineering retrons for industrial bacterial strain optimization.
Applications and Use Cases
Continuous directed evolution. Retrons can be reprogrammed every cell generation to introduce new variants at a defined locus, enabling continuous evolution of proteins inside living bacteria. This is the core of platforms being developed at Eligo Bioscience and Bits in Bio, among others.
Massively parallel functional genomics. CRISPEY in yeast lets researchers test thousands of point mutations in parallel by encoding them in retron libraries. The same principle is being adapted to mammalian cells.
Precision editing without exogenous template. The most therapeutically interesting application: pair a retron with a Cas9 nick or a prime editor and the cell produces its own repair template. This sidesteps the central bottleneck of HDR-based editing — getting enough template to enough cells.
Solving prime editing's template-delivery problem. Standard prime editing encodes its template in the pegRNA, which limits insertions to roughly 50 bp. Retrons can produce longer ssDNAs that act as repair templates after a prime editor nick — extending the practical insert size and improving efficiency. "Prime-Retron-Editor" architectures are being explored in academia and at startups.
Bacterial therapeutic strain engineering. Eligo Bioscience and other companies use retron-based recombineering to engineer phages and probiotic bacteria for clinical applications.
Retrons vs Standard Prime Editing
| Feature | Retron-assisted editing | Standard prime editing |
|---|---|---|
| Repair template source | Cell-generated ssDNA from cassette | Encoded in pegRNA 3′ extension |
| Template length | Potentially 100+ nt | ~30–50 nt practical |
| Template copies per cell | Hundreds to thousands | One per pegRNA molecule |
| Requires Cas-induced nick? | Often, yes | Yes |
| Mature in mammalian cells? | Improving — early stage | Yes |
| Continuous mutagenesis | Native capability | Not designed for this |
Connection to the Broader Gene Editing Ecosystem
Retrons sit at an interesting node in the editing toolkit. They can pair with CRISPR-Cas9, with base editors, and especially with prime editors — where they may eventually solve the template-size limit that drove the development of twin prime editing and PASTE. Like every other modern editor, they face the central delivery system challenge — although retrons partly mitigate it by amplifying their own active species inside the cell. The broader story is part of David Liu's vision of editing without breaks: retrons combined with nick-only editors avoid the dangers of double-strand breaks while delivering far more template than HDR alone can manage.
Current Limitations and Challenges
- Mammalian efficiency. Retron msDNA production is far less efficient in human cells than in E. coli. Codon optimization, RT engineering, and improved scaffolds are ongoing.
- Cargo size. A retron + RT + Cas9 + scaffold is a substantial expression cassette. Single-AAV delivery is hard.
- Off-target HDR. msDNAs can template repair at unintended nicks, especially if Cas off-target activity is high.
- Immunogenicity. Bacterial RTs are foreign proteins and may provoke immune responses.
- Template integrity. msDNA is partly RNA-DNA hybrid; how much of the molecule is actually used for HDR is still being characterized.
FAQ
What is msDNA?
Multi-copy single-stranded DNA — a chimeric RNA-DNA molecule produced by retron reverse transcriptases. Each bacterial cell can contain hundreds to thousands of copies.
What were retrons originally for?
They are part of bacterial anti-phage immune systems, acting as tripwires that detect phage proteins and trigger abortive infection.
How do retrons help prime editing?
Prime editing's template lives inside the pegRNA, which limits its size. Retrons can produce longer ssDNA templates inside the cell, potentially extending prime editing's insert size and efficiency.
Are retron therapies in clinical trials?
No. Retron-based editing is preclinical as of 2026. Most published work is in bacteria or yeast, with mammalian-cell results emerging in academic labs and startups.
What companies work on retrons?
Eligo Bioscience uses retrons in bacterial therapeutic engineering. Bits in Bio and several stealth startups are exploring retron-CRISPR hybrids. Most major CRISPR companies are evaluating retron technology internally.
Are retrons a replacement for HDR templates?
They are a way of producing HDR templates in situ rather than delivering them exogenously. The biology is the same; only the supply chain changes.
